These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

325 related articles for article (PubMed ID: 27000881)

  • 1. Translational Hurdles in Stroke Recovery Studies.
    Jolkkonen J; Kwakkel G
    Transl Stroke Res; 2016 Aug; 7(4):331-42. PubMed ID: 27000881
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Methodological quality of animal studies of neuroprotective agents currently in phase II/III acute ischemic stroke trials.
    Philip M; Benatar M; Fisher M; Savitz SI
    Stroke; 2009 Feb; 40(2):577-81. PubMed ID: 19074479
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Animal models of stroke: do they have value for discovering neuroprotective agents?
    Richard Green A; Odergren T; Ashwood T
    Trends Pharmacol Sci; 2003 Aug; 24(8):402-8. PubMed ID: 12915049
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Update on pharmacological strategies for stroke: prevention, acute intervention and regeneration.
    Legos JJ; Barone FC
    Curr Opin Investig Drugs; 2003 Jul; 4(7):847-58. PubMed ID: 14619407
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Translating promising preclinical neuroprotective therapies to human stroke trials.
    Cook DJ; Tymianski M
    Expert Rev Cardiovasc Ther; 2011 Apr; 9(4):433-49. PubMed ID: 21517728
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Amphetamine and other pharmacological agents in human and animal studies of recovery from stroke.
    Walker-Batson D; Mehta J; Smith P; Johnson M
    Prog Neuropsychopharmacol Biol Psychiatry; 2016 Jan; 64():225-30. PubMed ID: 25896190
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Toward wisdom from failure: lessons from neuroprotective stroke trials and new therapeutic directions.
    Gladstone DJ; Black SE; Hakim AM;
    Stroke; 2002 Aug; 33(8):2123-36. PubMed ID: 12154275
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Neuroprotection in brain ischemia--doubts and hopes].
    Zádor Z; Benyó Z; Lacza Z; Hortobágyi T; Harkány T; Hortobágyi T
    Ideggyogy Sz; 2004 Mar; 57(3-4):81-93. PubMed ID: 15133909
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Update on pharmacotherapy for stroke and traumatic brain injury recovery during rehabilitation.
    Liepert J
    Curr Opin Neurol; 2016 Dec; 29(6):700-705. PubMed ID: 27748687
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Strategies to improve post-stroke behavioral recovery in aged subjects.
    Buga AM; Bălşeanu A; Popa-Wagner A; Mogoantă L
    Rom J Morphol Embryol; 2009; 50(4):559-82. PubMed ID: 19942950
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Trafermin for stroke recovery: is it time for another randomized clinical trial?
    Paciaroni M; Bogousslavsky J
    Expert Opin Biol Ther; 2011 Nov; 11(11):1533-41. PubMed ID: 21883031
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Trial design and reporting standards for intra-arterial cerebral thrombolysis for acute ischemic stroke.
    Higashida RT; Furlan AJ; Roberts H; Tomsick T; Connors B; Barr J; Dillon W; Warach S; Broderick J; Tilley B; Sacks D; ;
    Stroke; 2003 Aug; 34(8):e109-37. PubMed ID: 12869717
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of MLC601 on functional recovery after stroke: A systematic review and meta-analysis of randomized controlled trials.
    González-Fraile E; Martín-Carrasco M; Ballesteros J
    Brain Inj; 2016; 30(3):267-70. PubMed ID: 26890534
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacological therapies in post stroke recovery: recommendations for future clinical trials.
    Chollet F; Cramer SC; Stinear C; Kappelle LJ; Baron JC; Weiller C; Azouvi P; Hommel M; Sabatini U; Moulin T; Tardy J; Valenti M; Montgomery S; Adams H
    J Neurol; 2014 Aug; 261(8):1461-8. PubMed ID: 24221642
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Future of neuroprotection for acute stroke: in the aftermath of the SAINT trials.
    Savitz SI; Fisher M
    Ann Neurol; 2007 May; 61(5):396-402. PubMed ID: 17420989
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recommendations for standards regarding preclinical neuroprotective and restorative drug development.
    Stroke Therapy Academic Industry Roundtable (STAIR)
    Stroke; 1999 Dec; 30(12):2752-8. PubMed ID: 10583007
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neurorestorative therapies for stroke: underlying mechanisms and translation to the clinic.
    Zhang ZG; Chopp M
    Lancet Neurol; 2009 May; 8(5):491-500. PubMed ID: 19375666
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Why do neuroprotective drugs work in animals but not humans?
    DeGraba TJ; Pettigrew LC
    Neurol Clin; 2000 May; 18(2):475-93. PubMed ID: 10757837
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacological Interventions and Rehabilitation Approach for Enhancing Brain Self-repair and Stroke Recovery.
    Szelenberger R; Kostka J; Saluk-Bijak J; Miller E
    Curr Neuropharmacol; 2020; 18(1):51-64. PubMed ID: 31362657
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A critical appraisal of the NXY-059 neuroprotection studies for acute stroke: a need for more rigorous testing of neuroprotective agents in animal models of stroke.
    Savitz SI
    Exp Neurol; 2007 May; 205(1):20-5. PubMed ID: 17408618
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.